However, the impact of US/China tensions could be one factor to impede growth. "We have seen well-established multi-national companies signing deals and licensing drugs from Chinese biotech firms: I-Mab and AbbVie, Novartis and BeiGene, Lilly and Innovent, to name a few," Zhang says. Investment opportunities in the Chinese biotech sector are already becoming apparent. There has also been a significant increase in investment through private funding the number of financing deals and total capital raised reached a record high in 2020. "Since 2018, more than four dozen biotech/medical device companies achieved initial public offerings on the Hong Kong stock exchange, raising billions of dollars to support the development of novel therapies," she says. Health care expenditure in China will rise rapidly over the next three decades, says Cinney Zhang, Fund Manager at AXA Investment Managers the need for treatments for neurodegenerative disorders, cancer, obesity, and genetic diseases has reinforced the need for an innovative biotech sector in the region. The US-dominated biotech landscape is evolving as aging populations and lifestyle-related diseases become global health issues, impacting Asia, as much as the rest of the world.
0 kommentar(er)
